Insulin degludec

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.

Switching 1% of standard bolus insulin lispro to a liver-targeted formulation decreases hypoglycemic events without affecting glucose control, OPTI-1 study findings indicate.

Insulin degludec offers similar glycemic outcomes to insulin glargine U100, along with more straightforward dosing, for people with insulin-treated diabetes crossing time zones, a small study suggests.

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.

Use of insulin degludec is associated with a reduced risk for recurrent nocturnal hypoglycemia as measured by hourly plasma glucose among adults with type 1 diabetes, suggest findings from the overnight substudy of the HypoDeg trial.

The SURPASS-3 findings show that people with type 2 diabetes can obtain better glycemic control with tirzepatide than insulin degludec, while losing rather than gaining weight.

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.